Abstract：
OBJECTIVE: To evaluate the clinical outcomes following bilateral implantation of the AcrySof™ IQ Vivity™ toric extended depth of focus (EDOF) intraocular lens (IOL).
METHODS: Prospective interventional case series.
METHODS: Patients with bilateral significant cataracts and pre-existing corneal astigmatism underwent cataract surgery and implantation with the AcrySof™ IQ Vivity™ toric IOL. Dominant eyes were targeted at emmetropia and non-dominant eyes at -0.50D. Primary endpoints were binocular uncorrected distance (UDVA), intermediate (UIVA at 66 cm) and near (UNVA at 40 cm) acuities at 3 months. Secondary outcomes were corrected distance (CDVA), distance corrected intermediate (DCIVA) and distance corrected near (DCNVA), refractive predictability, rotational stability, binocular defocus curve, contrast sensitivity, Questionnaire for Visual Disturbances (QUVID) and Visual Function Index (VF-14) questionnaire scores. All visual acuities were converted to logarithm of minimum angle of resolution (logMAR) for analysis.
RESULTS: 30 patients underwent uneventful phacoemulsification. The mean binocular UDVA, UIVA and UNVA were 0.06 ± 0.12, 0.11 ± 0.10 and 0.26 ± 0.10 respectively. The mean refractive spherical equivalent (MRSE) for dominant and non-dominant eyes were - 0.07D ± 0.27 and - 0.12D ± 0.54 respectively. 92.4% of dominant eyes and 84.6% of non-dominant eyes within 0.50D of target. The mean IOL rotation was 3.85° ± 5.09 with 86.7% of eyes with less than 5° of rotation. 26.7%, 20% and 36.7% of patients reported starbursts, haloes and glare respectively. The mean VF-14 score was 91.77.
CONCLUSIONS: Bilateral implantation of the AcrySof™ IQ Vivity™ Toric IOL resulted in very good unaided visual acuities for far and intermediate distance with functional near vision. Dysphotopsias were reported but despite this, a high level of visual function was achieved.
METHODS: Prospective interventional case series.
METHODS: Patients with bilateral significant cataracts and pre-existing corneal astigmatism underwent cataract surgery and implantation with the AcrySof™ IQ Vivity™ toric IOL. Dominant eyes were targeted at emmetropia and non-dominant eyes at -0.50D. Primary endpoints were binocular uncorrected distance (UDVA), intermediate (UIVA at 66 cm) and near (UNVA at 40 cm) acuities at 3 months. Secondary outcomes were corrected distance (CDVA), distance corrected intermediate (DCIVA) and distance corrected near (DCNVA), refractive predictability, rotational stability, binocular defocus curve, contrast sensitivity, Questionnaire for Visual Disturbances (QUVID) and Visual Function Index (VF-14) questionnaire scores. All visual acuities were converted to logarithm of minimum angle of resolution (logMAR) for analysis.
RESULTS: 30 patients underwent uneventful phacoemulsification. The mean binocular UDVA, UIVA and UNVA were 0.06 ± 0.12, 0.11 ± 0.10 and 0.26 ± 0.10 respectively. The mean refractive spherical equivalent (MRSE) for dominant and non-dominant eyes were - 0.07D ± 0.27 and - 0.12D ± 0.54 respectively. 92.4% of dominant eyes and 84.6% of non-dominant eyes within 0.50D of target. The mean IOL rotation was 3.85° ± 5.09 with 86.7% of eyes with less than 5° of rotation. 26.7%, 20% and 36.7% of patients reported starbursts, haloes and glare respectively. The mean VF-14 score was 91.77.
CONCLUSIONS: Bilateral implantation of the AcrySof™ IQ Vivity™ Toric IOL resulted in very good unaided visual acuities for far and intermediate distance with functional near vision. Dysphotopsias were reported but despite this, a high level of visual function was achieved.
摘要：
目的：评估双侧植入AcrySof™IQVivity™复曲面扩展焦深（EDOF）人工晶状体（IOL）后的临床结果。
方法：前瞻性介入病例系列。
方法：双侧明显白内障和预先存在角膜散光的患者接受了白内障手术并植入AcrySof™IQVivity™复曲面IOL。显性眼睛在-0.50D时瞄准正视眼和非显性眼睛。主要终点是双眼未校正距离（UDVA），3个月时的中间（66厘米的UIVA）和近（40厘米的UNVA）视力。次要结果是校正距离（CDVA），中间距离校正(DCIVA)和附近距离校正(DCNVA)，屈光可预测性，旋转稳定性,双眼散焦曲线,对比敏感度,视觉障碍问卷（QUVID）和视觉功能指数（VF-14）问卷得分。将所有视敏度转换为最小分辨率角(logMAR)的对数用于分析。
结果：30例患者接受了顺利的超声乳化手术。平均双眼UDVA，UIVA和UNVA分别为0.06±0.12、0.11±0.10和0.26±0.10。优势眼和非优势眼的平均折光等效球面（MRSE）分别为-0.07D±0.27和-0.12D±0.54。92.4%的优势眼和84.6%的非优势眼在目标0.50D内。平均IOL旋转为3.85°±5.09，其中86.7％的眼睛旋转小于5°。26.7%,20%和36.7%的患者报告了星暴，分别为光环和眩光。平均VF-14评分为91.77。
结论：双侧植入AcrySof™IQVivity™ToricIOL可在功能性近视力的远距离和中距离下获得非常好的裸眼视力。据报道，但尽管如此，达到了高水平的视觉功能。
方法：前瞻性介入病例系列。
方法：双侧明显白内障和预先存在角膜散光的患者接受了白内障手术并植入AcrySof™IQVivity™复曲面IOL。显性眼睛在-0.50D时瞄准正视眼和非显性眼睛。主要终点是双眼未校正距离（UDVA），3个月时的中间（66厘米的UIVA）和近（40厘米的UNVA）视力。次要结果是校正距离（CDVA），中间距离校正(DCIVA)和附近距离校正(DCNVA)，屈光可预测性，旋转稳定性,双眼散焦曲线,对比敏感度,视觉障碍问卷（QUVID）和视觉功能指数（VF-14）问卷得分。将所有视敏度转换为最小分辨率角(logMAR)的对数用于分析。
结果：30例患者接受了顺利的超声乳化手术。平均双眼UDVA，UIVA和UNVA分别为0.06±0.12、0.11±0.10和0.26±0.10。优势眼和非优势眼的平均折光等效球面（MRSE）分别为-0.07D±0.27和-0.12D±0.54。92.4%的优势眼和84.6%的非优势眼在目标0.50D内。平均IOL旋转为3.85°±5.09，其中86.7％的眼睛旋转小于5°。26.7%,20%和36.7%的患者报告了星暴，分别为光环和眩光。平均VF-14评分为91.77。
结论：双侧植入AcrySof™IQVivity™ToricIOL可在功能性近视力的远距离和中距离下获得非常好的裸眼视力。据报道，但尽管如此，达到了高水平的视觉功能。
